Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Abramson Cancer Center at Penn Medicine Clear all
Completed Phase 2 Interventional Results available

A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

NCT04288687
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Niraparib Pill
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Recruiting Phase 1 Interventional

Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas

NCT07478848
View directory record Official record
Conditions
Large B Cell Lymphoma, Non Hodgkin Lymphoma (NHL), Diffuse Large B Cell Lymphoma (DLBCL), Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B Cell Lymphoma Relapsed
Interventions
Vancomycin 125mg, Radiation Therapy, CAR-T
Drug · Radiation · Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Enrolling by invitation No phase listed Observational

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

NCT06332131
View directory record Official record
Conditions
Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Completed No phase listed Observational

Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMM

NCT01958528
View directory record Official record
Conditions
a Diagnosis of MGUS or SMM by IMWG Criteria
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Jul 23, 2026, 8:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pilot Study of an NTproBNP Guided Strategy of Cardioprotection

NCT04737265
View directory record Official record
Conditions
Cardiotoxicity, Toxicity Due to Chemotherapy, Breast Cancer, Lymphoma, Cardiomyopathies, Heart Failure
Interventions
Biomarker Guided Intervention
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • West Chester, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Enrolling by invitation No phase listed Observational

Allergy Delabeling in Antibiotic Stewardship - Evaluations

NCT06967467
View directory record Official record
Conditions
Beta Lactam Allergy in Patients With a Hematologic Malignancy
Interventions
Semi-structured interview, Survey, Ethnographic observation
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Active, not recruiting Phase 2 Interventional

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

NCT04827862
View directory record Official record
Conditions
Non Hodgkin Lymphoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Withdrawn No phase listed Observational

Mechanisms and Predictors of Unusual Radiation or Chemotherapy Toxicity

NCT02469194
View directory record Official record
Conditions
Severe or Mild Toxicity From Radiotherapy and/or Chemotherapy
Interventions
Blood Draw
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Jul 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Magnetic Resonance Imaging in Evaluating Response to RadiationTherapy in Patients With High Grade Glioma

NCT01018329
View directory record Official record
Conditions
Brain Tumor
Interventions
Magnetic Resonance Imaging, Diffusion Tensor Imaging, Magnetic Resonance Spectroscopic Imaging, Dynamic Contract-Enhanced magnetic resonance imaging, Diffusion-weighted magnetic resonance imaging
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Jul 23, 2026, 8:15 PM EDT
Active, not recruiting No phase listed Observational

Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases

NCT02159742
View directory record Official record
Conditions
Neoplastic Disease
Interventions
Data Collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Completed No phase listed Observational

A Prospective Study of Electronic Symptom Reporting Via Mobile Phone Among Patients With Advanced Non-Small Cell Lung Cancer

NCT03616522
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
a novel mobile phone-based intervention for automated electronic PRO collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Jul 23, 2026, 8:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

NCT00589056
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, etoposide, nelfinavir mesylate, protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 23, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

NCT00683241
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer
Interventions
DCVac-L
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2013 · Synced Jul 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Exercise and Colon Cancer

NCT02250053
View directory record Official record
Conditions
Stage II Colon Cancer, Stage III Colon Cancer
Interventions
Exercise
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jul 23, 2026, 8:15 PM EDT
Completed No phase listed Observational

LIVESTRONG Survivorship Care Plan: Continued Data Collection and Follow Up Survey

NCT02559323
View directory record Official record
Conditions
Cancer Patient
Interventions
Survey
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Jul 23, 2026, 8:15 PM EDT
Recruiting Not applicable Interventional

Integrating Telehealth to Advance Lung Cancer Screening

NCT06638554
View directory record Official record
Conditions
Early Detection of Cancer, Telemedicine, Decision Making
Interventions
Active Choice, Telehealth Only, Low Touch Strategy, High Touch Strategy
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
50 Years to 80 Years
Enrollment
6,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Increasing Screening for Cancer Using EHR-Nudges

NCT06177795
View directory record Official record
Conditions
Breast Cancer
Interventions
Post-visit patient text messaging, Default pended order, High risk bidirectional post-visit text messaging
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 74 Years · Female only
Enrollment
21,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Temzolomide and Gleevec in Advanced Melanoma

NCT00667953
View directory record Official record
Conditions
Melanoma, Advanced Melanoma
Interventions
Gleevec, Temodar
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Jul 23, 2026, 8:15 PM EDT
Completed Not applicable Interventional

Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain

NCT01013337
View directory record Official record
Conditions
Breast Cancer, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
acupuncture therapy, sham intervention
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Jul 23, 2026, 8:15 PM EDT
Active, not recruiting Not applicable Interventional

Penn Medicine Biobank Return of Results Program

NCT06089954
View directory record Official record
Conditions
Genetic Disease, Cancer, Cardiovascular Diseases
Interventions
private web-portal eHealth disclosure of genetic results, eHealth education intervention (web or chatbot)
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Terminated Phase 1 Interventional

Autologous OC-L Vaccine and Ovarian Cancer

NCT02452775
View directory record Official record
Conditions
Primary Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-L, Montanide, poly-ICLC (Hiltonol),
Biological · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 23, 2026, 8:15 PM EDT
Completed No phase listed Observational

Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts

NCT02246738
View directory record Official record
Conditions
Urothelial Carcinoma of the Bladder
Interventions
Blood Collection
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Jul 23, 2026, 8:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Implementation of eHealth Delivery Alternatives for Cancer Genetic Testing for Hereditary Cancer (eREACH3)

NCT07471958
View directory record Official record
Conditions
Cancer
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 8:15 PM EDT
Recruiting Phase 1 Interventional

FAPI-74 PET/CT in Adults With Fibrosis

NCT06413355
View directory record Official record
Conditions
Fibrosis (Morphologic Abnormality)
Interventions
[F-18]-FAPI-74
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 23, 2026, 8:15 PM EDT